← Oncology Approval Tracker

FDA DECISION ·

Brukinsa + obinutuzumab

zanubrutinib with obinutuzumab · BeiGene

Accelerated approvalNew or expanded indicationFollicular lymphoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with relapsed or refractory follicular lymphoma after two or more systemic treatment lines; use with obinutuzumab.

LAMPGEN ANALYSIS

Why it matters

The combination adds a BTK inhibitor and anti-CD20 option for previously treated follicular lymphoma.

What research teams should watch

Plan infusion premedication, infection screening and reconciliation of bleeding-risk medications alongside oral treatment.

PRIMARY RECORDS

Sources